Article

July 31, 2012

Jeff Lemieux and Jon Bumbaugh Discuss Hospital Readmission Rates

Jeff Lemieux, Senior Vice President, Center for Health Policy and Research, AHIP, and Jon Bumbaugh, Director of Statistics & Actuarial Services, MedAssurant, Inc, address preventing hospital readmissions.

Lemieux states that the study was set to examine the readmission rates in managed care compared with the rates in other studies in fee-for-service.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

July 15th 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

Medicaid | Image credit: Andrii - stock.adobe.com

July 10th 2025

Experts Highlight Consequences of Medicaid Rollbacks Due to Budget Bill

Julia Bonavitacola

A webinar held by KFF on July 9 emphasized the immediate effects of the new budget bill, highlighting the impacts on Medicaid and health spending in the next decade.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

July 7th 2025

Insurance Gaps Threaten Cancer Treatment Success

Maggie L. Shaw

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.

Constantine Farmakidis, MD | Image Credit: University of Kansas Medical Center

July 3rd 2025

A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD

Maggie L. Shaw Constantine Farmakidis, MD

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.